Background::　Cervical　cancer　is　the　second　most　common　cause　of　cancer　related　death　of　women.　Persistent　HPV　infection,　especially　with　high-risk　types　such　as　HPV16　and　HPV18,　has　been　identified　to　be　the　primary　cause　of　cervical　cancer.　E6　and　E7　are　the　major　oncoproteins　of　high-risk　HPVs,　which　are　expressed　exclusively　in　HPV　infected　tissues,　and　thereby　represent　ideal　therapeutic　targets　for　immunotherapy　of　cervical　cancer.　Materials　and　Methods:　In　this　work,　we　used　recombinant　adenovirus　expressing　coden-optimized　HPV16　E6　and　E7　fusion　protein　(Ad-ofE6E7)　to　prime　dendritic　cells　(DC-ofE6E7),　to　investigate　the　ability　of　primed　DC　vaccine　in　eliciting　antitumor　immunity　in　vitro　and　vivo.　Results:　Our　results　indicated　that　DC-ofE6E7　vaccine　co-culturing　with　splenocytes　could　strongly　induce　a　tumor-specific　cytotoxic　T　lymphocyte　(CTL)　response　and　kill　the　TC-1　cells　effectively　in　vitro.　Moreover,　DC-ofE6E7　vaccine　induced　protective　immunity　against　the　challenge　of　TC-1　cancer　cells　in　vivo.　Conclusions:　The　results　suggested　that　the　HPV16　ofE6E7　primed　DC　vaccine　has　potential　application　for　cervical　cancer　immunotherapy.